RxDoctor Payments Data

Jessica Dance

Family · Blackfoot, IDNPI 1538763909

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,929 of the $3,949 with a category attached, or 74.2%. 27 manufacturers reported payments, led by Medtronic at 37.2% of the total. 2025 is the largest year on record at $1,783, more than ten times the $154 reported in 2021. Among family clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,949in general payments, 2019–2025

Across 193 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Novartis$1K
  • Abbott$677
  • Johnson & Johnson$100
  • Cvrx, Inc.$58
  • Pfizer$54
  • plus $487 from 21 others

What the payments were for

  • Travel & lodging$1,02026%
  • Food & beverage$2,92974%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,949 in reported general payments places this provider in the 90th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$33,992
Medicare patients
163
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$99,005
XareltoRivaroxaban40$25,100
Repatha SureclickEvolocumab22$11,080
EntrestoSacubitril/Valsartan14$9,432
FarxigaDapagliflozin Propanediol11$6,135
Prasugrel Hcl11$4,785
Flecainide Acetate32$2,771
Metoprolol Succinate296$2,579
Potassium Chloride66$2,398
SotalolSotalol Hcl46$1,171
Diltiazem 12hr ErDiltiazem Hcl15$1,037
Diltiazem 24hr Er (Cd)Diltiazem Hcl33$885
Losartan Potassium100$681
Chlorthalidone38$568
Atorvastatin Calcium76$481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$99,005132 claims
Johnson & JohnsonXarelto$100$25,10040 claims
NovartisEntresto$1,106$9,43214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 809 family providers in Idaho.

Other family in Blackfoot

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →